^
Association details:
| Biomarker: | FLT3-ITD mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Regimen: | DA (cytarabine + daunorubicin) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Venetoclax + hypomethylating agents combined with dose-adjusted HAG for relapsed/refractory acute myeloid leukemia: Two case reports
Published date:
11/20/2020
Excerpt:
Case 1 involved a 23-year-old man who had suffered from AML for >4 years, and his FLT3 mutation status was positive at the initial diagnosis. After the first course of treatment with the standard-dose “Da” plan, the patient experienced complete remission....Genetic analyses showed that...the FLT3-ITD mutation was not present...
DOI:
10.1097/MD.0000000000023265
